A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC)

Liu D.Shen, LinLinShenAnanda, SumitraSumitraAnandaCao, DanDanCaoHan, Catherine HyeWonCatherine HyeWonHanCoward, JermaineJermaineCowardChao, YeeYeeChaoLi, WeiWeiLiDass, Prashanth HariPrashanth HariDassCHIH-HUNG HSUNagrial, AdnanAdnanNagrialHuang, YuanYuanHuangGanju, VinodVinodGanjuChen, XiaobingXiaobingChenCohen, Deirdre J.Deirdre J.CohenKumar, RajivRajivKumarBai, Li-YuanLi-YuanBaiYuan, YingYingYuanChiu, Tai-JanTai-JanChiu2026-01-232026-01-232024-01-010732183Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/735539falseA phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC)journal article2-s2.0-105023448604